An Analysis of Icahn’s Biogen Idec Strategy: Why Three Board Seats When Four Will Be Open?

Carl Icahn is making no bones about it—he is not happy with the way Biogen Idec handled its efforts to seek a buyer for the company, and so now he’s moving to take matters more into his own hands. That was the point behind Icahn’s announcement Monday that he plans to advance a slate of three candidates for Biogen’s board at its upcoming annual meeting. But what he didn’t explain is the reason he only asked for three board seats when four are coming up for vote: because he has no interest in trying to knock Biogen co-founder and MIT Nobel Laureate Phillip Sharp, one of the four directors slated for reelection, off the board. He is also well aware that a sale of the company might take a while and is positioning himself for a longer-term effort.

Those are two insights provided by a source close to Icahn’s thinking who asked not to be named, combined with a closer analysis of the investor’s announcement.

As laid out in general terms in Icahn’s press release, the bid for three board seats at the upcoming election (the date of which is not yet set but will likely happen by late spring) is part of a longer-term strategy to position Icahn to take control of the board at the 2009 annual meeting, when four more seats will be up for reelection. If Icahn were to win three seats this year and four next, the resulting seven seats would be enough to control the 12-person board. (That’s assuming it remains a 12-member board; Icahn is also proposing that Biogen’s bylaws be amended to fix the number of board seats at a dozen.)

Icahn is, of course, an astute investor and likely was under no illusions that things would be easy when he pushed late last year for a sale of Biogen—for reasons I’ll get to in a minute. But, as Icahn said in his press release, “We believe that the process was flawed in a number of key respects and that the process was run to placate us and other large shareholders who we believe asked for Biogen to find a buyer.” In particular, the statement cited the confidentiality agreement that prospective buyers were required to sign before they could talk to Elan Pharmaceuticals, Biogen’s partner on the key drug Tysabri, which is approved for treating multiple sclerosis and Crohn’s disease. (Elan holds some change-of-control rights on Tysabri that, if exercised, could discourage a sale of Biogen). Icahn stated, “We also believe that the confidentiality agreement was so restrictive that certain potential bidders were not able to sign the agreement and therefore were not able to participate in the bidding.”

Biogen director of public affairs Naomi Aoki told me, as she has said to other members of the press, that Biogen “ran what can only be described as a thorough, comprehensive process that was in keeping with industry standards.” And at an investor meeting earlier this month, Biogen CEO Jim Mullen also defended the process, saying it was like making an offer to buy a home, contingent on a final inspection, according to the Boston Globe. But that clearly was not how Icahn viewed it. He saw it more as prospective buyers being asked to make a significant commitment to purchase before they could even fully inspect the goods—a process that could make them nervous from the outset. Or, put another way, if a prospective buyer is going to spend $20 billion or so, it would like to talk to Elan directly from the get-go.

Indeed, Tysabri is central to the deal. And the biggest issue with the drug is a rare, often fatal brain infection called progressive multifocal leukoencephalopathy (PML) that occurred in three Tysabri users. In response to those cases, the drug was pulled from the market in February 2005. In July 2006 it was reintroduced under a strict prescribing and monitoring program; while there have been no new cases of PML in Tysabri users since that time, one theory—or fear—is that people who take the drug over a prolonged period might be more prone to the infection. That risk of an increased rate of the infection going forward is one reason even if companies could have easily negotiated with Elan, a sale might have been tough.

Our information is that Icahn understands that the question marks around Tysabri could mean that a sale … Next Page »

Single PageCurrently on Page: 1 2

Bob is Xconomy's founder and chairman. You can email him at Follow @bbuderi

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

One response to “An Analysis of Icahn’s Biogen Idec Strategy: Why Three Board Seats When Four Will Be Open?”

  1. dtuoiq npwuzai okryv lupajzqn kxuba xltwdjgze ehnprxwfz